DBV Technologies SA

DBV Technologies Reports First Quarter 2025 Financial Results

30 Apr 2025 15:00:00 By Nasdaq GlobeNewswire

DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document

11 Apr 2025 15:30:00 By Nasdaq GlobeNewswire

DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved

27 Mar 2025 21:30:05 By Nasdaq GlobeNewswire

DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results...

24 Mar 2025 01:30:00 By Nasdaq GlobeNewswire

DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress

25 Feb 2025 15:01:00 By Nasdaq GlobeNewswire

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

13 Jan 2025 15:05:00 By Nasdaq GlobeNewswire

DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study

08 Jan 2025 15:05:00 By Nasdaq GlobeNewswire

DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old

11 Dec 2024 15:05:00 By Nasdaq GlobeNewswire

Information regarding the total number of voting rights and  total number of shares of the Company as of November 30, 2024

02 Dec 2024 15:30:00 By Nasdaq GlobeNewswire

DBV Technologies Announces Plan to Implement ADS Ratio Change

11 Nov 2024 15:30:00 By Nasdaq GlobeNewswire

DBV Technologies Reports Third Quarter 2024 Financial Results

06 Nov 2024 15:30:00 By Nasdaq GlobeNewswire

DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe

22 Oct 2024 15:45:00 By Nasdaq GlobeNewswire

DBV Technologies to Participate in Upcoming ACAAI 2024 Congress

18 Oct 2024 15:30:00 By Nasdaq GlobeNewswire

Information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2024

14 Oct 2024 15:30:00 By Nasdaq GlobeNewswire

DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial

23 Sep 2024 15:30:00 By Nasdaq GlobeNewswire

DBV Technologies to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

04 Sep 2024 15:30:00 By Nasdaq GlobeNewswire

Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2024

02 Aug 2024 15:30:00 By Nasdaq GlobeNewswire

DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report

30 Jul 2024 16:30:00 By Nasdaq GlobeNewswire

DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results

30 Jul 2024 15:30:00 By Nasdaq GlobeNewswire

DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024

29 Jul 2024 00:30:00 By Nasdaq GlobeNewswire